292 related articles for article (PubMed ID: 20876851)
1. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
Finn JD; Ozelo MC; Sabatino DE; Franck HW; Merricks EP; Crudele JM; Zhou S; Kazazian HH; Lillicrap D; Nichols TC; Arruda VR
Blood; 2010 Dec; 116(26):5842-8. PubMed ID: 20876851
[TBL] [Abstract][Full Text] [Related]
2. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
[TBL] [Abstract][Full Text] [Related]
3. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
4. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
6. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
8. Complete short-term correction of canine hemophilia A by in vivo gene therapy.
Connelly S; Mount J; Mauser A; Gardner JM; Kaleko M; McClelland A; Lothrop CD
Blood; 1996 Nov; 88(10):3846-53. PubMed ID: 8916949
[TBL] [Abstract][Full Text] [Related]
9. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.
McCORMACK WM; Seiler MP; Bertin TK; Ubhayakar K; Palmer DJ; Ng P; Nichols TC; Lee B
J Thromb Haemost; 2006 Jun; 4(6):1218-1225. PubMed ID: 16706963
[TBL] [Abstract][Full Text] [Related]
10. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
Samelson-Jones BJ; Arruda VR
Front Immunol; 2020; 11():618. PubMed ID: 32425925
[TBL] [Abstract][Full Text] [Related]
11. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
13. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
[TBL] [Abstract][Full Text] [Related]
15. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
16. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
17. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
18. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells.
Qadura M; Othman M; Waters B; Chegeni R; Walker K; Labelle A; Ozelo M; Hough C; Lillicrap D
J Thromb Haemost; 2008 Dec; 6(12):2095-104. PubMed ID: 18826393
[TBL] [Abstract][Full Text] [Related]
19. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
[TBL] [Abstract][Full Text] [Related]
20. A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy.
Chen AC; Cai X; Li C; Khoryati L; Gavin MA; Miao CH
Front Immunol; 2020; 11():638. PubMed ID: 32411127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]